Federico Grossi Biography and Net Worth

Dr. Grossi was Potentia Pharmaceuticals’ clinical research director when he joined Apellis as the new company’s clinical research director in 2010. Dr. Grossi received his medical degree from the University of Cordoba, in Argentina, and his PhD degree in physiology from the University of Louisville, in Kentucky. Following his postgraduate training in surgery, Dr. Grossi joined the plastic surgery research laboratory at the University of Louisville, where he developed his expertise in microsurgery and composite tissue transplantation. He was a crucial member of the Louisville Face Transplant Team, whose publications on the ethical and psychological aspects of face transplantation are now considered hallmark publications in this field. He has also published numerous articles in the fields of ischemic preconditioning and composite tissue allotransplantation.

What is Federico Grossi's net worth?: The estimated net worth of Federico Grossi is at least $2.57 million as of January 5th, 2023. Dr. Grossi owns 94,884 shares of Apellis Pharmaceuticals stock worth more than $2,572,305 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Grossi may own. Learn More about Federico Grossi's net worth.
How do I contact Federico Grossi?: The corporate mailing address for Dr. Grossi and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Federico Grossi's contact information.
Has Federico Grossi been buying or selling shares of Apellis Pharmaceuticals?: Federico Grossi has not been actively trading shares of Apellis Pharmaceuticals within the last three months. Most recently, Federico Grossi sold 2,500 shares of the business's stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $48.79, for a transaction totalling $121,975.00. Following the completion of the sale, the insider now directly owns 94,884 shares of the company's stock, valued at $4,629,390.36. Learn More on Federico Grossi's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 33 times. They sold a total of 596,910 shares worth more than $33,545,080.32. The most recent insider tranaction occured on September, 16th when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,340,510.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 9/16/2024.

Federico Grossi Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/5/2023	Sell	2,500	$48.79	$121,975.00	94,884
12/1/2022	Sell	2,500	$49.93	$124,825.00	97,384
10/3/2022	Sell	2,500	$66.69	$166,725.00	102,384
8/1/2022	Sell	2,500	$55.99	$139,975.00	107,384
6/1/2022	Sell	2,500	$41.78	$104,450.00	109,561
5/2/2022	Sell	2,500	$43.56	$108,900.00	112,061
3/15/2022	Sell	375	$39.57	$14,838.75
2/15/2022	Sell	375	$45.43	$17,036.25
1/14/2022	Sell	375	$40.56	$15,210.00
11/1/2021	Sell	625	$30.70	$19,187.50
10/14/2021	Sell	750	$34.57	$25,927.50
7/14/2021	Sell	500	$64.68	$32,340.00
7/8/2021	Sell	250	$65.68	$16,420.00	63,680
6/14/2021	Sell	500	$61.84	$30,920.00	54,930
4/14/2021	Sell	500	$42.82	$21,410.00	56,214
4/1/2021	Sell	600	$43.41	$26,046.00	56,714
3/15/2021	Sell	500	$46.77	$23,385.00	57,314
3/5/2021	Sell	5,000	$48.62	$243,100.00	62,814
1/14/2021	Sell	4,000	$51.99	$207,960.00	35,827
12/1/2020	Sell	600	$48.25	$28,950.00
11/2/2020	Sell	600	$31.09	$18,654.00	27,725
9/1/2020	Sell	600	$31.58	$18,948.00	28,925
8/3/2020	Sell	600	$26.28	$15,768.00	29,525
7/1/2020	Sell	850	$32.43	$27,565.50	30,125

Federico Grossi Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $27.11

$26.65

$27.40

50 Day Range

MA: $29.45

$26.18

$38.36

2 Week Range

Now: $27.11

$24.34

$73.80

Volume

66,209 shs

Average Volume

1,894,226 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

“This Changes Everything” - Trump Hands Millions Massive IRS Gift

From Colonial Metals | Ad

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!